Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Equity Income: 2021-2025

Historic Equity Income for Beam Therapeutics (BEAM) over the last 5 years, with Sep 2025 value amounting to $4.9 million.

  • Beam Therapeutics' Equity Income rose 339.20% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 145.03%. This contributed to the annual value of -$14.1 million for FY2024, which is 24.20% up from last year.
  • As of Q3 2025, Beam Therapeutics' Equity Income stood at $4.9 million, which was up 11.82% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Equity Income peaked at $25.8 million during Q2 2021, and registered a low of -$25.5 million during Q3 2022.
  • Moreover, its 3-year median value for Equity Income was -$2.1 million (2024), whereas its average is -$2.3 million.
  • Its Equity Income has fluctuated over the past 5 years, first plummeted by 839.65% in 2022, then soared by 339.20% in 2025.
  • Beam Therapeutics' Equity Income (Quarterly) stood at -$4.3 million in 2021, then crashed by 421.26% to -$25.5 million in 2022, then spiked by 56.00% to -$722,000 in 2023, then tumbled by 50.97% to -$1.1 million in 2024, then soared by 339.20% to $4.9 million in 2025.
  • Its Equity Income stands at $4.9 million for Q3 2025, versus $4.4 million for Q2 2025 and -$2.1 million for Q1 2025.